Rein Therapeutics (RNTX) Return on Capital Employed (2017 - 2026)
Rein Therapeutics (RNTX) posted quarterly Return on Capital Employed of 433.73% for Q1 2026, down 31596.0% year-over-year from N/an in Q1 2025, and down 180.57% quarter-over-quarter from 154.59% in Q4 2025.
Rein Therapeutics (RNTX) Return on Capital Employed (2017 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Return on Capital Employed for 10 consecutive years, with 433.73% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 31596.0% year-over-year to 433.73%; the TTM figure through Mar 2026 stood at 433.73% (down 31596.0% YoY), while the FY2025 annual figure was 136.86%, down 5376.0% from the prior year.
- Return on Capital Employed slipped to 433.73% in Q1 2026 per RNTX's latest filing, from 154.59% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.83% in Q1 2024 and bottomed at 433.73% in Q1 2026.
- Historically, Return on Capital Employed has averaged 113.83% across 5 years, with a median of 116.18% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 12632 bps — and 2026, when it sank 31596 bps.
- Rein Therapeutics' Return on Capital Employed stood at 130.19% in 2022, then surged by 77 bps to 29.58% in 2023, then sank by 184 bps to 84.06% in 2024, then slumped by 84 bps to 154.59% in 2025, then sank by 181 bps to 433.73% in 2026.
- Business Quant data shows RNTX's Return on Capital Employed at 433.73% in Q1 2026, 154.59% in Q4 2025, and 121.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -135.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -135.79% |
| Mar 31, 2026 | -433.73% |
| Dec 31, 2025 | -154.59% |
| Sep 30, 2025 | -121.91% |
| Jun 30, 2025 | -123.04% |
| Mar 31, 2025 | -117.77% |
| Dec 31, 2024 | -84.06% |
| Sep 30, 2024 | -29.27% |
| Jun 30, 2024 | -25.68% |
| Mar 31, 2024 | -18.83% |
| Dec 31, 2023 | -29.58% |
| Sep 30, 2023 | -116.18% |
| Jun 30, 2023 | -126.51% |
| Mar 31, 2023 | -145.15% |
| Dec 31, 2022 | -130.19% |
| Sep 30, 2022 | -114.62% |
| Jun 30, 2022 | -94.37% |
| Mar 31, 2022 | -69.71% |
| Dec 31, 2021 | -56.47% |
| Sep 30, 2021 | -45.17% |